2022-07-12 11:58:32
#SLNO
Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
The presentations by Mr. Pittman and Ms. Bolding included the results from the analysis of caregiver interviews conducted after at least 12 months of investigational, open-label DCCR treatment. The interviews were available for 51 patients who were enrolled in the DCCR Phase 3 program. Casimir Inc (Casimir) completed semi-structured interviews with these participants and interview transcripts were manually coded by trained coders who subsequently analyzed the coded interviews in accordance with a pre-specified statistical analysis plan. Folia Health used the Casimir-prepared transcripts and conducted a semi-automated analysis using Natural Language Processing (NLP) methods.
In the Casimir analysis, 33 (65%), 30 (59%), and 31 (61%) caregivers described a positive change in food-related behavior, non-food-related behavior, and daily life, respectively. Of these, 26 (51%), 20 (39%), and 25 (49%), respectively, reported a positive change with major impact. The analysis was based on thematic coding of 12-month interview data by trained, blinded researchers.
The Folia Health NLP analysis of interview transcripts identified seven problematic behavior domains. 88% of participants experienced positive change in at least one behavior with DCCR treatment. Positive change was detected across all seven identified domains, most commonly in food seeking (72%) and daily life (73%).
"Both analyses of caregiver interviews presented at IPWSO summarize the positive changes across all seven identified behavioral domains, in both food- and non-food-related behaviors, as well as daily life, while receiving long-term DCCR. These findings, combined with the totality of data generated in our DCCR program, continue to support the potential DCCR has to be a safe and tolerable therapy that may provide meaningful benefit to people with PWS, caregivers, and families," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics.
154 viewsSacha Sil, edited 08:58
S
